Selective therapeutic efficacy of tyrosine kinase inhibitor sorafenib on the restoration of methylglyoxal-induced peritoneal fibrosis.

MLA

Wei, Yu-Syuan, et al. “Selective Therapeutic Efficacy of Tyrosine Kinase Inhibitor Sorafenib on the Restoration of Methylglyoxal-Induced Peritoneal Fibrosis.” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 176, July 2024, p. 116905. EBSCOhost, https://doi.org/10.1016/j.biopha.2024.116905.

APA

Wei, Y.-S., Wu, C.-H., Lin, S.-L., Tsai, S.-Y., Chen, Y.-T., & Tsai, P.-S. (2024). Selective therapeutic efficacy of tyrosine kinase inhibitor sorafenib on the restoration of methylglyoxal-induced peritoneal fibrosis. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 176, 116905. https://doi.org/10.1016/j.biopha.2024.116905

Chicago

Wei, Yu-Syuan, Ching-Ho Wu, Shuei-Liong Lin, Su-Yi Tsai, Yi-Ting Chen, and Pei-Shiue Tsai. 2024. “Selective Therapeutic Efficacy of Tyrosine Kinase Inhibitor Sorafenib on the Restoration of Methylglyoxal-Induced Peritoneal Fibrosis.” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 176 (July): 116905. doi:10.1016/j.biopha.2024.116905.